Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan 30;2(1):1-14.
doi: 10.3390/jpm2010001.

Personalized medicine and cancer

Mukesh Verma  1
Affiliations
Review

Personalized medicine and cancer

Mukesh Verma. J Pers Med. .

Abstract

Cancer is one of the leading causes of death in the United States, and more than 1.5 million new cases and more than 0.5 million deaths were reported during 2010 in the United States alone. Following completion of the sequencing of the human genome, substantial progress has been made in characterizing the human epigenome, proteome, and metabolome; a better understanding of pharmacogenomics has been developed, and the potential for customizing health care for the individual has grown tremendously. Recently, personalized medicine has mainly involved the systematic use of genetic or other information about an individual patient to select or optimize that patient's preventative and therapeutic care. Molecular profiling in healthy and cancer patient samples may allow for a greater degree of personalized medicine than is currently available. Information about a patient's proteinaceous, genetic, and metabolic profile could be used to tailor medical care to that individual's needs. A key attribute of this medical model is the development of companion diagnostics, whereby molecular assays that measure levels of proteins, genes, or specific mutations are used to provide a specific therapy for an individual's condition by stratifying disease status, selecting the proper medication, and tailoring dosages to that patient's specific needs. Additionally, such methods can be used to assess a patient's risk factors for a number of conditions and to tailor individual preventative treatments. Recent advances, challenges, and future perspectives of personalized medicine in cancer are discussed.

PubMed Disclaimer

References

    1. Stricker T., Catenacci D.V., Siewert S.Y. Molecular profiling of cancer—the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin. Oncol. 2011;38:173–185. doi: 10.1053/j.seminoncol.2011.01.013. - DOI - PubMed
    1. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., Fritz P., Simon W., Suman V.J., Ames M.M., Safgren S.L., Kuffel M.J., Ulmer H.U., Boländer J., Strick R., Beckmann M.W., Koelbl H, Weinshilboum R.M., Ingle J.N., Eichelbaum M., Schwab M., Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–1436. doi: 10.1001/jama.2009.1420. - DOI - PMC - PubMed
    1. Offit K. Personalized medicine: new genomics, old lessons. Hum. Genet. 2011;130:3–14. doi: 10.1007/s00439-011-1028-3. - DOI - PMC - PubMed
    1. Baehner F.L., Lee M., Demeure M.J., Bussey K.J., Kiefer J.A., Barrett M.T. Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J. Surg. Oncol. 2011;103:563–573. doi: 10.1002/jso.21838. - DOI - PubMed
    1. Song M., Lee K.M., Kang D. Breast cancer prevention based on gene-environment interaction. Mol. Carcinog. 2011;50:280–290. doi: 10.1002/mc.20639. - DOI - PubMed